Is Lisata Therapeutics Inc. (LSTA) overvalued? · rev $1.0M
Lisata Therapeutics Inc. (LSTA) is a biotechnology company listed on US.
This page asks whether Lisata Therapeutics Inc. (LSTA) looks expensive on cached numbers — not a short thesis.
Latest reported LSTA revenue for 2024-12-31 was $1.0M. Net income was -$20.0M. LSTA currently screens at market cap $31.7M.
LSTA currently screens at market cap $31.7M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next LSTA 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the LSTA stock page for the full model, not this heading.
Not investment advice.